Synthonics Names New CEO
Blacksburg, VA – October16, 2017 – Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that it has appointed John Tinkham as Chief Executive Officer and Chairman of the Board. He succeeds Ken Slepicka in these roles.
John Tinkham, a founder and director of the company, stated that “I am thankful for this opportunity and very excited by the challenges it presents. I look forward to working closely with our team and our partners to accelerate the development and commercialization of our lead compounds
Ken Slepicka, will remain with the company as a director and will focus his efforts on overseeing and monetizing the company’s novel cannabinoid purification process and its product development.
Dr. Tom Piccariello, President and Chief Science Officer of Synthonics stated that ”We are very pleased that John Tinkham has accepted the CEO position. We look forward to continued success of the company. We are also grateful to Ken Slepicka for his service to the company as CEO and we look forward to Ken’s new role to advance our cannabinoid projects."
Synthonics Receives License to Conduct Industrial Hemp Research
May 30, 2017
Synthonics, Inc. announced receipt of a license from the Commonwealth of Virginia's Department of Agriculture and Consumer Services (VDACS) to possess industrial hemp, which will allow Synthonics to research industrial hemp in their laboratory in Blacksburg, VA. This research will be conducted as a component of a VDACS-approved industrial hemp research program managed by a Virginia public institution of higher education.
Dr. Tom Piccariello, President and Chief Science Officer of Synthonics, stated: "We are very pleased that VDACS has granted us a license that will enable us to conduct research with industrial hemp. Industrial hemp could become a staple crop for the state of Virginia for many products. Our focus will be in applying the proprietary extraction process we have developed for use with medical marijuana to industrial hemp. The environmentally friendly process produces a purer (95% or more cannabinoid content) and more consistent powder in less time and at less cost than traditional purification processes. We believe that a pure powder of Cannabidiolic Acid (CBDA) from hemp leaves could have significant medical value. Recent preclinical studies have shown the potential medicinal benefits of CBDA, especially as therapy for anticipatory nausea in cancer patients on chemotherapy. CBDA also has anti-inflammatory and analgesic activity."
Ken Slepicka, CEO of Synthonics stated "Our goal is not only to develop a purification process of the hemp plant, but also to apply our metal coordinated technology to the pure CBDA that is derived from the hemp plant to produce a metallo-CBDA compound that can be more readily absorbed into the bloodstream to provide a faster onset of action for people with nausea and chronic pain. We are very excited for this opportunity to help people with these conditions through this license."